Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects |
| 2 | ACTIVE_COMPARATOR | PCV7 administration only, 85 subjects |
| 3 | ACTIVE_COMPARATOR | MenC-TT vaccine only, 85 subjects |
| Name | Type | Description |
|---|---|---|
| Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) | BIOLOGICAL | MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle |
| 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) | BIOLOGICAL | PCV7 (0.5 ml) to be administered in the right thigh muscle |
| Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) | BIOLOGICAL | MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle |
Inclusion Criteria: Male and female subjects will be eligible for participation in this study if: * they are toddlers, aged 12 to 18 months * they are clinically healthy (i.e. the physician would have no reservations vaccinating with a MenC conjugate vaccine, and/or PCV7 outside the scope of a cli...